drugset / Trial / NCT07400003
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.
Timeline
- Start
- 2026-01-06
- Primary completion
- 2026-05-31
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lyophilized herpes zoster virus mRNA vaccine | Messenger RNA (mRNA) | — | — |
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | — |
| Comparator | herpes zoster attenuated live vaccine | Vaccine | — | — |